Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors

[1]  J. Strosberg Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[2]  Donghong Wang,et al.  Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. , 2013, Surgery.

[3]  A. Bellizzi,et al.  Overexpression of Membrane Proteins in Primary and Metastatic Gastrointestinal Neuroendocrine Tumors , 2013, Annals of Surgical Oncology.

[4]  J. Howe,et al.  Translational research in endocrine surgery. , 2013, Surgical oncology clinics of North America.

[5]  K. Shah,et al.  Surgery for metastatic neuroendocrine tumors with occult primaries. , 2013, The Journal of surgical research.

[6]  A. Bellizzi Assigning Site of Origin in Metastatic Neuroendocrine Neoplasms: A Clinically Significant Application of Diagnostic Immunohistochemistry , 2013, Advances in anatomic pathology.

[7]  M. V. van Velthuysen,et al.  Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry. , 2013, European journal of cancer.

[8]  H. Lehnert,et al.  [Diagnostics and therapy for neuroendocrine neoplasia of an unknown primary - a plea for open exploration]. , 2013, Zentralblatt fur Chirurgie.

[9]  Mohid S. Khan,et al.  Molecular Pathogenesis of Neuroendocrine Tumors: Implications for Current and Future Therapeutic Approaches , 2013, Clinical Cancer Research.

[10]  W. Harmsen,et al.  Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[11]  D. Hörsch,et al.  The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Y. Menda,et al.  The Value of Preoperative Imaging in Small Bowel Neuroendocrine Tumors , 2013, Annals of Surgical Oncology.

[13]  J. Fletcher,et al.  Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. , 2012, Surgery.

[14]  P. Spanheimer,et al.  Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling. , 2012, Surgery.

[15]  M. Falconi,et al.  Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases , 2012, The British journal of surgery.

[16]  K. Öberg,et al.  Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Hanlin L. Wang,et al.  Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin , 2012, Modern Pathology.

[18]  A. Ganetsky,et al.  Gastroenteropancreatic Neuroendocrine Tumors: Update on Therapeutics , 2012, The Annals of pharmacotherapy.

[19]  S. Dry,et al.  Multisite Validation Study to Determine Performance Characteristics of a 92-Gene Molecular Cancer Classifier , 2012, Clinical Cancer Research.

[20]  J. Mezhir,et al.  Comparison of Clinicopathologic Factors in 122 Patients with Resected Pancreatic and Ileal Neuroendocrine Tumors from a Single Institution , 2012, Annals of Surgical Oncology.

[21]  E. Baudin,et al.  ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary , 2011, Neuroendocrinology.

[22]  M. Falconi,et al.  ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors , 2011, Neuroendocrinology.

[23]  T. Gress,et al.  ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas , 2011, Neuroendocrinology.

[24]  F. Eggeling,et al.  Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases , 2011, Clinical & Experimental Metastasis.

[25]  M. Falconi,et al.  Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review , 2011, Neuroendocrinology.

[26]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[27]  M. Choti,et al.  Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis , 2010, Annals of Surgical Oncology.

[28]  E. Nakakura,et al.  Identification of Unknown Primary Tumors in Patients With Neuroendocrine Liver Metastases , 2010, Archives of surgery.

[29]  C. Schade-Brittinger,et al.  Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  G. Åkerström,et al.  Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors , 2008, World Journal of Surgery.

[32]  B. Diggs,et al.  Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. , 2006, Surgery.

[33]  D. Nagorney,et al.  Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. , 2003, Journal of the American College of Surgeons.

[34]  U. Henschke,et al.  Value of preoperative , 1966 .

[35]  Fynn Rw One hundred years after. , 1959 .

[36]  W. M. Barclay Surgery , 1894, Bristol medico-chirurgical journal.

[37]  S. Dry,et al.  A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors , 2014, Modern Pathology.

[38]  E. Bs,et al.  Population-Level Analysis of Pancreatic Neuroendocrine Tumors 2 cm or Less in Size , 2013, Annals of Surgical Oncology.

[39]  J. Stockman,et al.  Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .

[40]  V. Ambrosini,et al.  Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  R. Jensen,et al.  Gastroenteropancreatic neuroendocrine tumours. , 2008, The Lancet. Oncology.